Skip to Content
Merck
All Photos(1)

Documents

D8517

Sigma-Aldrich

Iron–Dextran

95-105 mg/mL (Iron content), solution

Synonym(s):

Ferric hydroxide dextran complex

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
9004-66-4
MDL number:
MFCD00081553
UNSPSC Code:
12352201
NACRES:
NA.25

biological source

synthetic

Quality Level

200

sterility

aseptically filled

Assay

95-105 mg/mL (Iron content)

form

solution

contains

0.5% phenol as preservative

composition

Iron, ~100 mg/mL

color

brown

useful pH range

4 - 6.5

storage temp.

room temp

InChI

1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)

InChI key

MVZXTUSAYBWAAM-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Iron-Dextran (ferric hydroxide dextran complex) may be used as an intravenous iron delivery preparation. Iron-Dextran may be used to induce iron-overload to study its effects and preventative measures.

Other Notes

To gain a comprehensive understanding of our extensive range of Dextrans for your research, we encourage you to visit our Carbohydrates Category page.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H317,H350

Hazard Classifications

Carc. 1B - Skin Sens. 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zachariah DeFilipp et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 9(1), 129-132 (2012-08-08)
Iron deficiency is a major postoperative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. Our objective was to evaluate the effectiveness and safety of a
C Egger et al.
Ultraschall in der Medizin (Stuttgart, Germany : 1980), 33(6), 587-592 (2012-11-17)
To check the feasibility of the easy quantification of tumor vascularization derived from dynamic contrast-enhanced ultrasound (DCE-US) in comparison to dynamic contrast-enhanced computed tomography (DCE-CT) in patients with hepatocellular carcinoma (HCC). 19 patients with cirrhosis and histologically proven HCC prospectively
Maureen M Okam et al.
American journal of hematology, 87(11), E123-E124 (2012-09-12)
Oral iron replacement is the standard therapy in iron-deficiency anemia (IDA). However, 59% of patients have gastrointestinal toxicity. With impaired iron uptake from the gastrointestinal tract (in anemia of chronic disease (ACD) or after bariatric surgery), suboptimal responsiveness to exogenous
Priya Prakash Karmali et al.
Molecular pharmaceutics, 9(3), 539-545 (2012-01-17)
Premature recognition and clearance of nanoparticulate imaging and therapeutic agents by macrophages in the tissues can dramatically reduce both the nanoparticle half-life and delivery to the diseased tissue. Grafting nanoparticles with hydrogels prevents nanoparticulate recognition by liver and spleen macrophages
V J Kumpf et al.
DICP : the annals of pharmacotherapy, 24(2), 162-166 (1990-02-01)
Parenteral iron therapy is indicated in patients with iron-deficiency anemia associated with conditions that interfere with the ingestion or absorption of oral iron. Replacement doses of iron required to replenish iron stores are based on body weight and the observed
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service